Skip to main content

Advertisement

Log in

The impact of sex and age on distribution of metastases in patients with renal cell carcinoma

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

Our objective was to investigate age and sex-related discrepancies on distribution of metastases in patients with metastatic renal cell carcinoma (RCC).

Methods

Within the National Inpatient Sample database (2008–2015) we identified 9607 patients with metastatic RCC. Trend test and Chi-square test analyses were used to evaluate the relationship between age and site of metastases, according to sex.

Results

Of 9607 patients with metastatic RCC, 6344 (65.9%) were men and 3263 (34.1%) were women. Thoracic, abdominal, bone and brain metastases were present in 51.1 vs. 52.8%, 42.6 vs. 44.3%, 29.9 vs. 29.2% and 8.6 vs. 8.8% of men vs. women, respectively. Increasing age was associated with decreasing rates of thoracic (from 55.5 to 48.5%) and brain (from 8.6 to 5.8%) metastases in men and with decreasing rates of abdominal (from 48.3 to 39.6%), bone (from 32.6 to 24.9%) and brain (from 8.8 to 5.4%) metastases in women. (all p < 0.05). Rates of concomitant metastatic sites also decreased with increasing age, from 57.1 to 50.8% in men and from 54.1 to 50.2% in women.

Conclusions

Important age and sex-related differences exist in the distribution of RCC metastases. The distribution of metastases is marginally different between sexes. Specifically, more advanced age is associated with lower rates of thoracic and brain metastases in men and with lower rates of abdominal, bone and brain metastases in women. Age and sex should be take into consideration into the staging management strategy, as well as into the follow-up strategy of patients with metastatic RCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Capitanio U, Bensalah K, Bex A et al (2019) Epidemiology of renal cell carcinoma. Eur Urol 75:74–84. https://doi.org/10.1016/j.eururo.2018.08.036

    Article  PubMed  Google Scholar 

  2. Palumbo C, Pecoraro A, Rosiello G et al (2020) Renal cell carcinoma incidence rates and trends in young adults aged 20–39 years. Cancer Epidemiol 67:101762. https://doi.org/10.1016/j.canep.2020.101762

    Article  PubMed  Google Scholar 

  3. Patel HD, Gupta M, Joice GA et al (2019) Clinical stage migration and survival for renal cell carcinoma in the United States. Eur Urol Oncol 2:343–348. https://doi.org/10.1016/j.euo.2018.08.023

    Article  PubMed  Google Scholar 

  4. Mir MC, Capitanio U, Bertolo R et al (2018) Role of active surveillance for localized small renal masses. Eur Urol Oncol 1:177–187. https://doi.org/10.1016/j.euo.2018.05.001

    Article  PubMed  Google Scholar 

  5. Capitanio U, Montorsi F (2016) Renal cancer. Lancet 387:894–906. https://doi.org/10.1016/S0140-6736(15)00046-X

    Article  PubMed  Google Scholar 

  6. Rosiello G, Palumbo C, Knipper S et al (2020) Comparison of survival outcomes in patients with metastatic papillary vs. clear- cell renal cell carcinoma: a propensity-score analysis. World J Urol. https://doi.org/10.1007/s00345-020-03187-y

    Article  PubMed  PubMed Central  Google Scholar 

  7. Larcher A, Wallis CJD, Bex A et al (2019) Individualised indications for cytoreductive nephrectomy: which criteria define the optimal candidates? Eur Urol Oncol 2:365–378. https://doi.org/10.1016/j.euo.2019.04.007

    Article  PubMed  Google Scholar 

  8. Palumbo C, Pecoraro A, Knipper S et al (2019) Survival and complication rates of metastasectomy in patients with metastatic renal cell carcinoma treated exclusively with targeted therapy: a combined population-based analysis. Anticancer Res 39:4357–4361. https://doi.org/10.21873/anticanres.13604

    Article  PubMed  Google Scholar 

  9. Larcher A, Fallara G, Rosiello G et al (2020) Cytoreductive nephrectomy in metastatic patients with signs or symptoms: implications for renal cell carcinoma guidelines. Eur Urol 78:321–326. https://doi.org/10.1016/j.eururo.2020.05.014

    Article  PubMed  Google Scholar 

  10. de Velasco G, Bex A, Albiges L et al (2019) Sequencing and combination of systemic therapy in metastatic renal cell carcinoma. Eur Urol Oncol 2:505–514. https://doi.org/10.1016/j.euo.2019.06.022

    Article  PubMed  Google Scholar 

  11. Palumbo C, Knipper S, Dzyuba-Negrean C et al (2020) Complication rates, failure to rescue and in-hospital mortality after cytoreductive nephrectomy in the older patients. J Geriatr Oncol 11:718–723. https://doi.org/10.1016/j.jgo.2019.06.005

    Article  PubMed  Google Scholar 

  12. Bianchi M, Sun M, Jeldres C et al (2012) Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol 23:973–980. https://doi.org/10.1093/annonc/mdr362

    Article  CAS  PubMed  Google Scholar 

  13. National (Nationwide) Inpatient Sample (NIS) n.d. https://www.hcup-us.ahrq.gov/news/exhibit_booth/nis_brochure.jsp (accessed 19 May 2020)

  14. Zaffuto E, Bandini M, Moschini M et al (2018) Location of metastatic bladder cancer as a determinant of in-hospital mortality after radical cystectomy. Eur Urol Oncol 1:169–175. https://doi.org/10.1016/j.euo.2018.02.001

    Article  PubMed  Google Scholar 

  15. Chandrasekar T, Klaassen Z, Goldberg H et al (2017) Metastatic renal cell carcinoma: patterns and predictors of metastases—a contemporary population-based series. Urol Oncol Semin Orig Investig 35:661.e7-661.e14. https://doi.org/10.1016/j.urolonc.2017.06.060

    Article  Google Scholar 

  16. Motzer RJ, Memorial Sloan Kettering Cancer Center Þ, Jonasch E, et al (2020) Continue NCCN guidelines panel disclosures NCCN guidelines version 1.2021 Kidney Cancer

  17. Sánchez-Ortiz RF, Rosser CJ, Madsen LT et al (2004) Young age is an independent prognostic factor for survival of sporadic renal cell carcinoma. J Urol 171:2160–2165. https://doi.org/10.1097/01.ju.0000125487.96469.2e

    Article  PubMed  Google Scholar 

  18. Sakaguchi S, Goto H, Hanibuchi M et al (2010) Gender difference in bone metastasis of human small cell lung cancer, SBC-5 cells in natural killer-cell depleted severe combined immunodeficient mice. Clin Exp Metastasis 27:351–359. https://doi.org/10.1007/s10585-010-9333-0

    Article  CAS  PubMed  Google Scholar 

  19. Rosiello G, Palumbo C, Knipper S et al (2020) Unmarried men have worse oncologic outcomes after radical cystectomy for nonmetastatic urothelial bladder cancer. Urol Oncol Semin Orig Investig 38:76.e1-76.e9. https://doi.org/10.1016/j.urolonc.2019.10.018

    Article  CAS  Google Scholar 

  20. Rosiello G, Knipper S, Palumbo C et al (2019) Unmarried status is a barrier for access to treatment in patients with metastatic renal cell carcinoma. Int Urol Nephrol 51:2181–2188. https://doi.org/10.1007/s11255-019-02266-3

    Article  PubMed  Google Scholar 

  21. Luzzago S, Palumbo C, Rosiello G et al (2020) Racial and ethnic differences in survival in contemporary metastatic renal cell carcinoma patients, according to alternative treatment modalities. Cancer Causes Control 31:263–272. https://doi.org/10.1007/s10552-020-01270-8

    Article  PubMed  Google Scholar 

  22. Heng DYC, Xie W, Regan MM et al (2013) External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol 14:141–148. https://doi.org/10.1016/S1470-2045(12)70559-4

    Article  PubMed  PubMed Central  Google Scholar 

  23. Zaghloul MS, Boutrus R, El-Hossieny H et al (2010) A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer. Int J Clin Oncol 15:382–389. https://doi.org/10.1007/s10147-010-0074-5

    Article  CAS  PubMed  Google Scholar 

  24. Deuker M, Stolzenbach F, Rosiello G et al (2020) Renal cell carcinoma: comparison between variant histology and clear cell carcinoma across all stages and treatment modalities. J Urol 204:671–676. https://doi.org/10.1097/JU.0000000000001063

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Author information

Authors and Affiliations

Authors

Contributions

GR: project development, data collection, data analyses, manuscript writing. AP: data collection, manuscript editing; MD: data collection, manuscript editing; LFS: data collection, manuscript editing; TM: data collection, manuscript editing; ZT: data analyses; AL: manuscript editing; UC: manuscript editing; FM: manuscript editing; SFS: manuscript editing; AK: manuscript editing; FS: manuscript editing; AB: manuscript editing; PIK: Project development, manuscript writing.

Corresponding author

Correspondence to Giuseppe Rosiello.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

Not applicable.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rosiello, G., Pecoraro, A., Deuker, M. et al. The impact of sex and age on distribution of metastases in patients with renal cell carcinoma. Int J Clin Oncol 26, 962–970 (2021). https://doi.org/10.1007/s10147-021-01874-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-021-01874-3

Keywords

Navigation